Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia (AML) Clinical Trial

Official title:

A Phase I/II Study of Eltrombopag in Elderly Patients With AML

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01113502
• Other study ID #: UPCC 17409
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: June 2010
• Est. completion date: November 10, 2015

Study information

• Verified date: July 2021
• Source: Abramson Cancer Center of the University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I/II open label study being conducted to evaluate the overall safety and initial effectiveness of an investigational drug, Eltrombopag in patients who are 60 years of age and older and who have Acute Myelogenous Leukemia (AML). Eltrombopag is an investigational drug, which means it has not been approved by the U.S. Food and Drug Administration (FDA) for use in this type of disease. Approximately 35 people will be enrolled on this study at the University of Pennsylvania

Description:

Primary Objectives (Phase I Portion): 1). To determine the safety and tolerability of eltrombopag in elderly subjects with AML 2). To determine the maximally tolerated initial starting dose of eltrombopag for elderly subjects with AML Primary Objectives (Phase II portion): 1). To better define the safety and tolerability of eltrombopag in elderly patients with AML at the maximally tolerated starting dose Page 9 of 18 determined in Phase I portion of study. 2). To determine the incidence of peripheral platelet count improvement (using baseline and response parameters as defined below) for subjects with disease related thrombocytopenia. Secondary Objectives (Phase I and II): 1). To preliminarily determine the efficacy (using AML response criteria as defined below) of eltrombopag in elderly subjects with AML. 2). To perform ex-vivo analyses using subject AML samples and stock eltrombopag to 1) assess leukemic proliferative capacity and 2) investigate potential eltrombopag induced cytoxic mechanisms for leukemic cell death. 3). To perform pharmacodynamic assessments of drug activity in leukemic cells using subject samples collected at various time points before and during drug exposure. 4). To preliminarily correlate pharmacodynamic findings with clinical response.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 44
• Est. completion date: November 10, 2015
• Est. primary completion date: March 14, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• A diagnosis of non-M3 AML which is either: a). Relapsed after standard chemotherapy or transplant;
• Newly diagnosed in a patient who is not an appropriate or willing candidate for standard induction chemotherapy - Age equal to or greater than 60 - Platelet count less than 75 - ECOG performance status of 0-2
• Life expectancy of at least 4 weeks
• Must be able to consume oral medication
• Must have recovered from toxic effects of prior chemotherapy
• Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
• For Phase I portion only: Subject must be of non-East Asian (Japanese, Chinese, Taiwanese or Korean) descent.
• For Phase II portion subject can be either East Asian or non-East Asian descent.

Exclusion Criteria:

• Cytotoxic chemotherapy (including azacitidine or decitabine) within the past 28 days other than hydroxyurea
• Active participation in any other investigational treatment study for AML.
• Known HIV or Hepatitis C
• ECOG performance status greater than 2
• Uncontrolled intercurrent illness including, but not limited to: uncontrolled ongoing infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Previous therapy with romiplostim or any other TPO-R agonist

Related Conditions & MeSH terms

• Acute Myelogenous Leukemia (AML)
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• Eltrombopag
Oral formulation taken daily

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center of the University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximally Tolerated Dose of Eltrombopag for Elderly Subjects With AML in Phase 1 Group	The maximal tolerated dose of eltrombopag for elderly subjects with AML will be defined as the number of dose limiting toxicities per dosing level.	The time from first day of therapy until subject is off study treatment, an average of 10 weeks.
Primary	Tolerability of Maximum Dose in Phase II Cohort	The tolerability of eltrombopag in elderly patients with AML at the maximally tolerated starting dose determined in Phase I portion of study will be assessed by the number of dose limiting toxicities in the Phase II dosing cohort. Clinical assessment and laboratory evaluation of Adverse Events and DLTs will be done according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP).	The time from first day of therapy to the first four weeks of therapy.
Primary	The Safety of Eltrombopag for Elderly Subjects With AML in Phase 1 Group	Safety of eltrombopag will be measured as the number of Grade 3 or higher adverse events per dosing level in Phase 1 group related to Eltrombopag. Relatedness is defined as event being assessed as unlikely, possibly, probably and definitely related to Eltrombopag. All events meeting these assessment categories will be considered related, and those assessed as Grade 3 or higher are reported for each dose level.	First day of study treatment to 30 days after last study treatment, an average of 10 weeks.
Primary	Safety of Eltrombopag in Patients With AML in Phase II Cohort.	Safety of eltrombopag will be measured as the number of Serious Adverse Events in Phase II group related to Eltrombopag. Relatedness is defined as event being assessed as unlikely, possibly, probably and definitely related to Eltrombopag. All Serious Adverse Events meeting these assessment categories will be considered related and are reported for the Phase II cohort.	First day of study treatment to 30 days after last study treatment, an average of 7 weeks.
Primary	Number of Participants With Peripheral Platelet Count Response in Phase I Cohort	Peripheral platelet count response is defined by number of participants in each dosing cohort exhibiting a peripheral platelet count response using the IWG modified Hematologic Improvement response criteria: For patients with counts less than 100,000/ul: 1) For patients with baseline platelet of > 20,000/ul, absolute increase of platelet count by at least 30,000 /ul 2) For patients with baseline platelets < 20,000/ul, an increase to > 20,000/ul and by at least 100%.	First day of study treatment to 30 days after last study treatment, an average of 10 weeks.
Secondary	Overall Response Rate (Phase I and Phase II)	This will include subjects who achieve a complete remission (CR) based on definitions by the International Working Group (IWG). CR is defined as the participant have a neutrophil Count>1000/ul, platelet count of >100,000/ul, bone Marrow Blasts < 5% and having no evidence of extramedullary disease.	The time from first day of therapy to time when subject achieves a complete remission (CR), based on the definition of the International Working Group (IWG), approximately 30 days.